Therefore, G-CSF-mobilized neutrophils could have a pro-tumor response when entering the tumor milieu, as we show here, and treating cancer patients with G-CSF alone for neutropenia may be an important issue to reconsider unless dexamethasone can be used simultaneously to reduce the inherent MDSC activity. This evidence concerns the gene CSF3 and Decreased total neutrophil count.